- Conditions
- Advanced Solid Tumor, Locally Advanced Solid Tumor, Metastatic Solid Tumor, Platinum-resistant Ovarian Cancer, Post Anti-PD-1 Melanoma, 2L+ Cervical Cancer, Neoadjuvant Melanoma, Neoadjuvant Non-Small Cell Lung Cancer, Post Anti-PD-(L)1 Non-Small Cell Lung Cancer, Post Anti-PD-(L)1 Small Cell Lung Cancer, Third Line or Later (3L+) HER2+ Breast Cancer, Second or Third Line (2L/3L) Cervical Cancer, Third-line or Later (3L+) Platinum-resistant Ovarian Cancer (PROC)
- Interventions
- TransCon IL-2 β/γ, Pembrolizumab, Chemotherapy drug, TransCon TLR7/8 Agonist, Surgery, Trastuzumab, Trastuzumab emtansine (T-DM1)
- Drug · Procedure
- Lead sponsor
- Ascendis Pharma Oncology Division A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 320 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 14
- States / cities
- Los Angeles, California • Springfield, Illinois • Louisville, Kentucky + 10 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 405
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Colorectal Neoplasms, Gastrointestinal Neoplasms
- Interventions
- JNJ-89402638, Bevacizumab, FOLFOX, FOLFIRI
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 260 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 6
- States / cities
- Tucson, Arizona • Aurora, Colorado • Sarasota, Florida + 3 more
- Conditions
- Advanced Solid Tumor Cancer
- Interventions
- X-PACT
- Combination Product
- Lead sponsor
- Immunolight, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 4
- States / cities
- Washington D.C., District of Columbia • Charlotte, North Carolina • Durham, North Carolina + 1 more
- Conditions
- Multiple Myeloma
- Interventions
- Dexamethasone, Daratumumab, Venetoclax, Bortezomib
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 156 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2031
- U.S. locations
- 14
- States / cities
- Aurora, Colorado • Tampa, Florida • Atlanta, Georgia + 10 more
- Conditions
- Multiple Myeloma
- Interventions
- Bortezomib, Melphalan, Autologous Stem Cell Transplant, Fludarabine, Allogeneic Stem Cell Transplant
- Drug · Procedure
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2019
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Metastatic Castrate Resistant Prostate Cancer
- Interventions
- Docetaxel, Radium 223
- Drug · Radiation
- Lead sponsor
- Tufts Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • Detroit, Michigan • Columbus, Ohio
- Conditions
- Advanced or Metastatic Non-small Cell Lung Cancer
- Interventions
- Rilvegostomig, Cisplatin, Carboplatin, Pemetrexed, Paclitaxel, Nab-paclitaxel, Ramucirumab
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 152 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 10
- States / cities
- Phoenix, Arizona • Santa Rosa, California • Jacksonville, Florida + 6 more
- Conditions
- Progressive Metastatic Castrate Resistant Prostate Cancer
- Interventions
- Tulmimetostat DL1 QD, Tulmimetostat DL2 QD, Tulmimetostat DL3 QD, Tulmimetostat Doses 1 or 2 QD, Tulmimetostat RP2D QD, JSB462 Dose 1 QD, JSB462 Dose 2 QD, JSB462 QD, Standard of Care (SoC)
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 188 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 8
- States / cities
- Denver, Colorado • Jacksonville, Florida • Atlanta, Georgia + 5 more
- Conditions
- Leukemia, Lymphocytic, Chronic, B-Cell
- Interventions
- CC-122, Ibrutinib, Obinutuzumab
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 8
- States / cities
- La Jolla, California • Boston, Massachusetts • Hackensack, New Jersey + 5 more
- Conditions
- Solid Tumor, B-Raf Mutation-Related Tumors
- Interventions
- Brimarafenib
- Drug
- Lead sponsor
- MapKure, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 109 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 5
- States / cities
- Beverly Hills, California • Boston, Massachusetts • New York, New York + 2 more
- Conditions
- X-Linked Retinitis Pigmentosa
- Interventions
- BIIB112
- Biological
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 10 Years and older · Male only
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 5
- States / cities
- Gainesville, Florida • Miami, Florida • Portland, Oregon + 2 more
- Conditions
- Advanced Solid Tumors Cancer
- Interventions
- ABBV-927, ABBV-181
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 163 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Chicago, Illinois • Boston, Massachusetts + 4 more
- Conditions
- Cancer, Hematologic Malignancies, Leukemia, Myeloid Leukemia
- Interventions
- Arm 1- Dose Escalation, Arm 2- Dose Expansion
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 3
- States / cities
- Stony Brook, New York • Cleveland, Ohio • Houston, Texas
- Conditions
- Advanced Solid Tumors, CRPC, mCRPC, Metastatic Castrate-resistant Prostate Cancer, PT-112, Prostatic Neoplasms, Genital Neoplasms, Male, Urogenital Neoplasms, Neoplasms by Site
- Interventions
- PT-112 Injection
- Drug
- Lead sponsor
- Promontory Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 109 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2025
- U.S. locations
- 17
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Duarte, California + 14 more
- Conditions
- Systemic Lupus Erythematosus, Lupus Nephritis, Idiopathic Inflammatory Myopathies, Diffuse Cutaneous Systemic Sclerosis
- Interventions
- CNTY-101, IL-2, Lymphodepleting Chemotherapy
- Biological · Drug
- Lead sponsor
- Century Therapeutics, Inc.
- Industry
- Eligibility
- 17 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Sacramento, California • Chicago, Illinois + 3 more
- Conditions
- Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Interventions
- Mosunetuzumab, Tocilizumab, Venetoclax, Rituximab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 332 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2032
- U.S. locations
- 5
- States / cities
- Rochester, Minnesota • New York, New York • Columbus, Ohio + 2 more
- Conditions
- Malignant Melanoma
- Interventions
- IMCgp100
- Drug
- Lead sponsor
- Immunocore Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2017
- U.S. locations
- 4
- States / cities
- Los Angeles, California • New Haven, Connecticut • New York, New York + 1 more
- Conditions
- Graft vs Host Disease
- Interventions
- Pacritinib
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 2
- States / cities
- Miami, Florida • Bethesda, Maryland
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Acute Mixed-Phenotype Leukemia, Cancer, Refractory, Progression, Diffuse Large B Cell Lymphoma, Multiple Myeloma, Lymphoma, Lymphoma, Non-Hodgkin, Myeloma, Plasma-Cell, Myelomatosis, Plasma Cell Myeloma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Interventions
- BMF-219
- Drug
- Lead sponsor
- Biomea Fusion Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 17
- States / cities
- Irvine, California • Los Angeles, California • Sacramento, California + 13 more
- Conditions
- Advanced Solid Malignancies
- Interventions
- CFI-402411, Pembrolizumab
- Drug
- Lead sponsor
- Treadwell Therapeutics, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 170 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 9
- States / cities
- La Jolla, California • Los Angeles, California • New Haven, Connecticut + 6 more
- Conditions
- Advanced or Metastatic Solid Tumors
- Interventions
- MDK-703, Checkpoint Inhibitor, Immune
- Drug
- Lead sponsor
- Medikine, Inc.
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 6
- States / cities
- Sarasota, Florida • Huntersville, North Carolina • Austin, Texas + 3 more
- Conditions
- Colorectal Cancer, Colorectal Neoplasms, Colorectal Carcinoma, Colorectal Tumors, Neoplasms, Colorectal
- Interventions
- NUC-3373 + leucovorin, NUC-3373, NUFOX, NUFOX + VEGF pathway inhibitor, NUFOX + EGFR inhibitor, NUFIRI, NUFIRI + VEGF pathway inhibitor, NUFIRI + EGFR inhibitor, NUC-3373 + bevacizumab
- Drug
- Lead sponsor
- NuCana plc
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 111 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 6
- States / cities
- Boston, Massachusetts • Durham, North Carolina • Nashville, Tennessee + 2 more
- Conditions
- Advanced Solid Tumors
- Interventions
- mRNA-4359, Pembrolizumab, Ipilimumab, Nivolumab
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 361 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2032
- U.S. locations
- 16
- States / cities
- Los Angeles, California • San Francisco, California • Aurora, Colorado + 11 more
- Conditions
- Locally Advanced or Metastatic Solid Tumor
- Interventions
- Rebastinib, Paclitaxel
- Drug
- Lead sponsor
- Deciphera Pharmaceuticals, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 177 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • Aurora, Colorado • Chicago, Illinois + 10 more